(NASDAQ: INMB) Inmune Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.
Inmune Bio's earnings in 2025 is -$42,082,000.On average, 1 Wall Street analyst forecast INMB's earnings for 2025 to be -$36,229,891, with the lowest INMB earnings forecast at -$36,229,891, and the highest INMB earnings forecast at -$36,229,891. On average, 1 Wall Street analyst forecast INMB's earnings for 2026 to be -$42,879,682, with the lowest INMB earnings forecast at -$42,879,682, and the highest INMB earnings forecast at -$42,879,682.
In 2027, INMB is forecast to generate -$37,835,013 in earnings, with the lowest earnings forecast at -$37,835,013 and the highest earnings forecast at -$37,835,013.